2905-56-8 | 1-Benzylpiperidine

Packsize	Purity	Availability	Price	Discounted Price
5g	98%	in stock	$22.00	$16.00
25g	98%	in stock	$41.00	$29.00

Description

• Catalog Number: AB33720
• Chemical Name: 1-Benzylpiperidine
• CAS Number: 2905-56-8
• Molecular Formula: C12H17N
• Molecular Weight: 175.2701
• MDL Number: MFCD00224901
• SMILES: C1CCN(CC1)Cc1ccccc1

Computed Properties

• Complexity: 132
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 13
• Hydrogen Bond Acceptor Count: 1
• Rotatable Bond Count: 2
• XLogP3: 2.6

Literature

• Estrogenic effects and their action mechanism of the major active components of party pill drugs.

  Toxicology letters 20121115

• Modeling anti-HIV compounds: the role of analogue-based approaches.

  Current computer-aided drug design 20120901

• Synthesis of novel N-benzyl substituted piperidine amides of 1H-indole-5-carboxylic acid as potential inhibitors of cholinesterases.

  Acta poloniae pharmaceutica 20120101

• Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.

  Journal of medicinal chemistry 20111222

• Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE).

  European journal of medicinal chemistry 20110101

• Design, synthesis, and pharmacological evaluation of haloperidol derivatives as novel potent calcium channel blockers with vasodilator activity.

  PloS one 20110101

• Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads.

  The Journal of biological chemistry 20101224

• Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors.

  European journal of medicinal chemistry 20101201

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Intramolecular NH···Pt interactions of platinum(II) diimine complexes with phenyl ligands.

  Inorganic chemistry 20101101

• Hydride transfer reactions via ion-neutral complex: fragmentation of protonated N-benzylpiperidines and protonated N-benzylpiperazines in mass spectrometry.

  Journal of mass spectrometry : JMS 20100501

• Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease.

  Journal of medicinal chemistry 20091126

• Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine.

  The Journal of pharmacology and experimental therapeutics 20090401

• Electrophoretically mediated microanalysis technique as a tool for the rapid screening of novel acetylcholinesterase inhibitors.

  Acta poloniae pharmaceutica 20090101

• Antiprion activity of functionalized 9-aminoacridines related to quinacrine.

  Bioorganic & medicinal chemistry 20080715

• From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.

  Bioorganic & medicinal chemistry letters 20080115

• Zwitterionic (4-benzyl-piperidinium-1-yl-meth-yl)phospho-nate.

  Acta crystallographica. Section E, Structure reports online 20080101

• Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

  Neuropsychiatric disease and treatment 20070601

• Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats.

  Basic & clinical pharmacology & toxicology 20060401

• Is subnanomolar binding affinity required for the in vivo imaging of acetylcholinesterase? Studies on 18F-labeled G379.

  Nuclear medicine and biology 20060101

• Design and synthesis of N-benzylpiperidine-purine derivatives as new dual inhibitors of acetyl- and butyrylcholinesterase.

  Bioorganic & medicinal chemistry 20051215

• Human acetylcholinesterase inhibitors: electronic-topological and neural network approaches to the structure-activity relationships study.

  Mini reviews in medicinal chemistry 20050501

• Discovery of melanin-concentrating hormone receptor R1 antagonists using high-throughput synthesis.

  Bioorganic & medicinal chemistry 20050301

• Subtype selective NMDA receptor antagonists: evaluation of some novel alkynyl analogues.

  Bioorganic & medicinal chemistry letters 20040308

• Aromatic amino-acid residues at the active and peripheral anionic sites control the binding of E2020 (Aricept) to cholinesterases.

  European journal of biochemistry 20031101

• Structure-activity relationship studies of highly selective inhibitors of the dopamine transporter: N-benzylpiperidine analogues of 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine.

  Journal of medicinal chemistry 20030410

• Syntheses and reactivities of disubstituted and trisubstituted fluorous pyridines with high fluorous phase affinities: solid state, liquid crystal, and ionic liquid-phase properties.

  The Journal of organic chemistry 20021004

• Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block.

  Bioorganic & medicinal chemistry letters 20020916

• NR2B selective NMDA receptor antagonists.

  Current pharmaceutical design 20020101

• Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors.

  Journal of medicinal chemistry 20010816

• [Application of neural networks using the volume learning algorithm for the study of structure-activity relationship in chemical compounds].

  Bioorganicheskaia khimiia 20010101